Accresa Health Secures Second U.S. Patent

The direct primary care technology company, based in Carrollton, Texas, received U.S. Patent No. 12,770,120 B2 covering healthcare affiliate management and payment technology.

Updated on Nov. 10, 2026 in Healthcare

Accresa Health Secures Second U.S. Patent

Accresa Health, a direct primary care technology company in Carrollton, Texas, has been issued its second U.S. patent, No. 12,770,120 B2. The company says it intends to enforce its patent rights against firms commercializing technology it considers infringing.

Why it matters

The patents cover affiliate management, healthcare network administration, and payment technology used in direct primary care and other subscription-based healthcare models. Accresa claims to be the only known DPC technology platform holding issued U.S. patents, which could shape competition in that segment.

Accresa holds two issued U.S. patents, No. 12,682,329 B2 and No. 12,770,120 B2, with the newer patent granted after the first. The filings do not specify which competitors are targeted for enforcement.

The players

Accresa Health

Accresa Health is a direct primary care technology company based in Carrollton, Texas, that builds affiliate management and payment infrastructure for subscription-based healthcare models.

The details

The second patent covers affiliate management, healthcare network administration, and payment technology that manage relationships and financial transactions among employers, healthcare providers, medical groups, and patients. Accresa states it intends to aggressively protect its intellectual property and pursue enforcement against companies it believes are commercializing infringing technology.

November 10, 2026: Accresa announced issuance of its second U.S. patent.

Industry Context

Accresa's patents protect the back-office affiliate management and payment systems underpinning direct primary care, a subscription model in which patients pay a recurring fee to a physician practice. By claiming issued U.S. patents in this niche, the company positions its platform as proprietary infrastructure within that model.

Patients enrolled in direct primary care memberships may see administrative and payment systems tied to proprietary platforms like Accresa's. The patents do not, by themselves, change what patients pay or how care is delivered.

The takeaway

Patent ownership in direct primary care technology may influence which administrative platforms practices can use in the years ahead. Readers tracking DPC costs should watch whether enforcement actions follow.